DAPAGLIFLOZIN (Farxiga) prior authorization at CareFirst BCBS
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
CareFirst BCBS requires prior-authorization documentation for DAPAGLIFLOZIN (Farxiga): a diagnosis with ICD-10 code, documented step-therapy history, and prescriber attestation of medical necessity. Standard PA decisions return on the clock printed in the current member-specific payer source; if denied, use the appeal window printed on the denial notice to appeal.
The PA criteria you'll need to meet
CareFirst BCBS reviews DAPAGLIFLOZIN (Farxiga) prior authorizations against its medical policy . CareFirst BCBS-specific context: BCBS licensee for Maryland, DC, and northern Virginia (~3.5M members). Operates as non-profit. Appeals jurisdiction depends on policy issue location — MIA (MD), DISB (DC), or SCC Bureau of Insurance (VA). CVS Caremark is the PBM.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in this class
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- CareFirst BCBS's medical policy URL referenced in the cover letter
Denial scenarios to check against the current policy
These are preparation scenarios, not frequency claims. Use only those supported by the current member-specific source:
- DC/MD/VA cross-jurisdiction issues
- Step therapy on specialty drugs via CVS Caremark
- Behavioral health network adequacy
- BlueChoice HMO referral denials
DAPAGLIFLOZIN (Farxiga)-specific review scenarios and context
Check whether the current notice cites any of these label-, REMS-, or policy-related scenarios:
- Step therapy
- Non-formulary
Brand: Farxiga. SGLT2 with heart-failure indication.
Manufacturer patient-assistance program: Farxiga BMS — relevant when a CareFirst BCBS denial sticks and the patient needs bridge access while appealing.
How CareFirst BCBS approaches Non-GLP-1 diabetes medications PAs
For DAPAGLIFLOZIN (FARXIGA), check whether the current CareFirst BCBS Non-GLP-1 diabetes medications policy cites step therapy on specialty drugs via cvs caremark. Pharmacy-benefit review for DAPAGLIFLOZIN (FARXIGA) at CareFirst BCBS is routed through CVS Caremark. The applicable review clock depends on the member's current product, whether the request is complete and urgent, and governing plan rules. Confirm receipt and timing with CareFirst BCBS; if denied, use the filing date and route printed on that denial notice. Check whether the current CareFirst BCBS SGLT2 or DPP-4 policy has an exception tied to an FDA-labeled cardiovascular or renal-protective indication (HFrEF, CKD stage 3-4, established ASCVD). CareFirst BCBS is domiciled in MD, so unresolved appeals escalate to the MD insurance department's external-review program for fully-insured policies (self-funded ERISA plans route to the DOL EBSA instead).
If the PA is denied
Verify the appeal window and decision clock in the current denial notice and member-specific payer source before relying on either. Submit through the provider portal (https://provider.carefirst.com) with the same packet plus an applicable, current clinical source supporting DAPAGLIFLOZIN (Farxiga)for the patient's indication.
Helping a patient appeal the denial directly? See the consumer guide: How to appeal a CareFirst BCBS denial on DenialHelp.
Contact CareFirst BCBS
- Provider portal: https://provider.carefirst.com
Frequently asked questions
What documentation does CareFirst BCBS need for DAPAGLIFLOZIN (Farxiga) prior auth?
CareFirst BCBS's typical PA packet for DAPAGLIFLOZIN (Farxiga): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis.
What's the turnaround time at CareFirst BCBS?
Verify the decision clock in the current member-specific payer policy and request receipt. Product type, urgency, state law, and plan terms can change the applicable timing; this page does not supply an operational deadline.
What documentation issues should be checked for DAPAGLIFLOZIN (Farxiga) at CareFirst BCBS?
Preparation scenarios to check against the current notice and policy include: DC/MD/VA cross-jurisdiction issues; Step therapy on specialty drugs via CVS Caremark; Behavioral health network adequacy. These are not measured frequency claims. For DAPAGLIFLOZIN (Farxiga), verify whether the actual denial raises step therapy, indication, or another plan-specific criterion before responding.
Does CareFirst BCBS waive step therapy on DAPAGLIFLOZIN (FARXIGA) for cardiovascular or renal indications?
Most plans including CareFirst BCBS waive standard step therapy when the chart documents an FDA-labeled cardiovascular or renal indication for the requested SGLT2 (HFrEF, CKD with eGFR 25-90 and albuminuria, established ASCVD). Submit the prior-auth packet with the specific FDA-labeled indication cited, the cardiology or nephrology supporting note, and the relevant lab evidence (NT-proBNP, eGFR trend, UACR). Pharmacy-benefit handling is routed through CVS Caremark. External-review escalation for CareFirst BCBS fully-insured policies sits with the MD insurance department.
How do I prep for a peer-to-peer with CareFirst BCBS on DAPAGLIFLOZIN (Farxiga)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Related PA criteria
Generate the DAPAGLIFLOZIN (Farxiga) PA packet
Open ApprovalHelp — generate a DAPAGLIFLOZIN (Farxiga) prior-auth packet tailored to CareFirst BCBS's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com